146 related articles for article (PubMed ID: 9212919)
41. Tissue disposition of 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys.
Yu RZ; Geary RS; Monteith DK; Matson J; Truong L; Fitchett J; Levin AA
J Pharm Sci; 2004 Jan; 93(1):48-59. PubMed ID: 14648635
[TBL] [Abstract][Full Text] [Related]
42. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.
Agrawal S; Temsamani J; Tang JY
Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7595-9. PubMed ID: 1881900
[TBL] [Abstract][Full Text] [Related]
43. Pharmacology of therapeutic oligonucleotides.
Diasio RB; Zhang R
Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):239-43. PubMed ID: 9212918
[No Abstract] [Full Text] [Related]
44. Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines.
Wagner RW; Matteucci MD; Lewis JG; Gutierrez AJ; Moulds C; Froehler BC
Science; 1993 Jun; 260(5113):1510-3. PubMed ID: 7684856
[TBL] [Abstract][Full Text] [Related]
45. Antiviral activity and ocular kinetics of antisense oligonucleotides designed to inhibit CMV replication.
Henry SP; Miner RC; Drew WL; Fitchett J; York-Defalco C; Rapp LM; Levin AA
Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2646-51. PubMed ID: 11581212
[TBL] [Abstract][Full Text] [Related]
46. Antisense therapeutics.
Agrawal S; Zhao Q
Curr Opin Chem Biol; 1998 Aug; 2(4):519-28. PubMed ID: 9736926
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration.
Zhang R; Iyer RP; Yu D; Tan W; Zhang X; Lu Z; Zhao H; Agrawal S
J Pharmacol Exp Ther; 1996 Aug; 278(2):971-9. PubMed ID: 8768755
[TBL] [Abstract][Full Text] [Related]
48. In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue.
Iversen P
Anticancer Drug Des; 1991 Dec; 6(6):531-8. PubMed ID: 1772568
[TBL] [Abstract][Full Text] [Related]
49. Bioanalysis considerations on the pharmacokinetic evaluation of antisense therapeutics.
Norris DA; Post N; Yu RZ; Greenlee S; Wang Y
Bioanalysis; 2019 Nov; 11(21):1909-1912. PubMed ID: 31648523
[No Abstract] [Full Text] [Related]
50. Distribution and excretion of a phosphorothioate oligonucleotide in rats with experimentally induced renal injury.
Masarjian L; de Peyster A; Levin AA; Monteith DK
Oligonucleotides; 2004; 14(4):299-310. PubMed ID: 15665597
[TBL] [Abstract][Full Text] [Related]
51. Comparative pharmacokinetics, tissue distribution, and tumor accumulation of phosphorothioate, phosphorodithioate, and methylphosphonate oligonucleotides in nude mice.
DeLong RK; Nolting A; Fisher M; Chen Q; Wickstrom E; Kligshteyn M; Demirdji S; Caruthers M; Juliano RL
Antisense Nucleic Acid Drug Dev; 1997 Apr; 7(2):71-7. PubMed ID: 9149842
[TBL] [Abstract][Full Text] [Related]
52. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice.
Raynaud FI; Orr RM; Goddard PM; Lacey HA; Lancashire H; Judson IR; Beck T; Bryan B; Cotter FE
J Pharmacol Exp Ther; 1997 Apr; 281(1):420-7. PubMed ID: 9103525
[TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides.
Geary RS; Yu RZ; Levin AA
Curr Opin Investig Drugs; 2001 Apr; 2(4):562-73. PubMed ID: 11566019
[TBL] [Abstract][Full Text] [Related]
54. Clearance kinetics, biodistribution, and organ saturability of phosphorothioate oligodeoxynucleotides in mice.
Rifai A; Brysch W; Fadden K; Clark J; Schlingensiepen KH
Am J Pathol; 1996 Aug; 149(2):717-25. PubMed ID: 8702009
[TBL] [Abstract][Full Text] [Related]
55. Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides.
Iwamoto N; Butler DCD; Svrzikapa N; Mohapatra S; Zlatev I; Sah DWY; Meena ; Standley SM; Lu G; Apponi LH; Frank-Kamenetsky M; Zhang JJ; Vargeese C; Verdine GL
Nat Biotechnol; 2017 Sep; 35(9):845-851. PubMed ID: 28829437
[TBL] [Abstract][Full Text] [Related]
56. A specific picomolar hybridization-based ELISA assay for the determination of phosphorothioate oligonucleotides in plasma and cellular matrices.
Wei X; Dai G; Marcucci G; Liu Z; Hoyt D; Blum W; Chan KK
Pharm Res; 2006 Jun; 23(6):1251-64. PubMed ID: 16718617
[TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetics of antisense analogues in the central nervous system.
Szklarczyk A; Kaczmarek L
Neurochem Int; 1997 Sep; 31(3):413-23. PubMed ID: 9246683
[TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species.
Geary RS; Yu RZ; Watanabe T; Henry SP; Hardee GE; Chappell A; Matson J; Sasmor H; Cummins L; Levin AA
Drug Metab Dispos; 2003 Nov; 31(11):1419-28. PubMed ID: 14570775
[TBL] [Abstract][Full Text] [Related]
59. Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo.
Leamon CP; Cooper SR; Hardee GE
Bioconjug Chem; 2003; 14(4):738-47. PubMed ID: 12862426
[TBL] [Abstract][Full Text] [Related]
60. Cholesteryl-conjugated phosphorothioate oligodeoxynucleotides modulate CYP2B1 expression in vivo.
Desjardins J; Mata J; Brown T; Graham D; Zon G; Iversen P
J Drug Target; 1995; 2(6):477-85. PubMed ID: 7773609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
